Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-23-003850
Filing Date
2023-03-15
Accepted
2023-03-15 16:30:52
Documents
55
Period of Report
2023-01-31

Document Format Files

Seq Description Document Type Size
1 z3723010q.htm   iXBRL 10-Q 793168
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 8338
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 8008
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6796
  Complete submission text file 0001214659-23-003850.txt   3847363

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzm-20230131.xsd EX-101.SCH 37186
6 XBRL CALCULATION FILE alzm-20230131_cal.xml EX-101.CAL 32029
7 XBRL DEFINITION FILE alzm-20230131_def.xml EX-101.DEF 129195
8 XBRL LABEL FILE alzm-20230131_lab.xml EX-101.LAB 269629
9 XBRL PRESENTATION FILE alzm-20230131_pre.xml EX-101.PRE 213905
49 EXTRACTED XBRL INSTANCE DOCUMENT z3723010q_htm.xml XML 521760
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 23735662
SIC: 2834 Pharmaceutical Preparations